POLIO VACCINES
"Salk" = I(nactivated) PV : Now (not before) is as
immunogenic as the OPV)
"Sabin" = O(ral live attenuated) PV
- No cases of wild-type polio inf. reported in pts.
successfully immunized with either IPV or OPV
- No cases of vaccine-strain polio in IPV recipients
- No wild-type polio reported in US since 1979 (as of 1994
or so
- 80 cases of vaccine-strain polio in OPV vaccine
recipients between '69 & '83 (amounts to 1 case per
3.2-8 million doses of vaccine dist'd for recipients,
less for their household contacts)--mostly adults; 10-15%
of cases immunodeficient; since 1980, avg. of 8-9 cases a
year reported of vaccine-associated paralytic polio. Risk
is about 1 case per 750,000 children receiving their
first dose of OPV. In immunocompromised persons can be
fatal
- IOM review found "evidence favored acceptance of a
causal relationship" between OPV and Guillain-Barre
sd. But has been superceded? Unclear from MMWR 45:RR-2,
1996.
- So DON'T give OPV to immunodeficient kids or
immunodeficient adults; use IPV instead. Also condider
IPV instead of OPV for immunocompetent adults. Use IPV
for kids who live with an immunodeficient person
(congenital immunodeficiency, HIV, leukemia, lymphoma,
generalized malignancy). If a household contact of an
immunodeficient person is inadvertently given OPV, avoid
close contact for 4-6wks; if can't avoid, at least do
good handwashing after contact with feces or saliva.
- In kids with immunodeficient or unimmunized household
contacts, consider giving IPV to these contacts. They
must have all 3 IPV's before give 1st OPV to kid. Can
give as little as 4 wks apart. No serious side effects of
IPV reported. (MMWR 45:8, 1996)
- In 1996, ACIP, AAP, and AAFP recommended 3 options for
polio vaccination: all IPV, all OPV, or IPV x 2 then OPV
x 2 (preferred per ACIP). This will "facilitate a
transition to exclusive use of IPV following further
progress toward global polio eradication" (JAMA
277:371, 1997). Timing is same for all 3 regimens except
that 3rd dose can be given 6-18mos for all-OPV; for the
sequential or all-IPV regimen, the 3rd dose should be at
12-18mos.
- In pregnancy: "Although no conclusive evidence
documents the adverse effects of OPV or IPV in pregnant
women and their developing fetuses, vaccination of
pregnant women should be avoided. However, if immediate
protection against poliomyelitis is necessary, OPV or IPV
can be given" (MMWR 45:8, 1996)